Kotrazol 200mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent effective against a variety of fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Kotrazol is indicated for the treatment of systemic and superficial mycoses, including aspergillosis, histoplasmosis, blastomycosis, and onychomycosis, as well as for infections caused by dermatophytes and Candida species. The capsule formulation allows for oral administration with improved bioavailability when taken with food. Dosage should be individualized based on the severity and type of infection, with typical regimens ranging from 100mg to 200mg once or twice daily. Caution is advised in patients with hepatic impairment, as itraconazole is metabolized primarily by the liver, and periodic liver function monitoring is recommended during prolonged therapy. Potential adverse effects include gastrointestinal disturbances, headache, rash, and, rarely, hepatotoxicity or cardiac effects such as congestive heart failure. Drug interactions are significant due to itraconazole’s inhibition of cytochrome P450 enzymes, necessitating careful review of concomitant medications. Kotrazol 200mg Capsule should be used under medical supervision to ensure efficacy and safety.